Biotech RadarJobs updated

COMPANY

EMD Serono

emdserono.com ↗

Status: Acquired, now part of Merck KGaA · How status works

FDA-approved therapeutic company Past trials only

79 open jobs · last seen Oct 23, 2026 · 50 sources

Profile checked Oct 10, 2026

Keywords: Multiple Sclerosis Systemic Lupus Erythematosus Ovarian Cancer Parkinson's Disease Dyskinesia Relapsing-remitting Multiple Sclerosis Non Small Cell Lung Carcinoma Relapsing Multiple Sclerosis Non Small Cell Lung Cancer Melanoma Glioblastoma Rheumatoid Arthritis Glioblastoma Multiforme HIV Infections Lipodystrophy Anovulation Lung Cancer Prostate Cancer N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma Leukemia, Myeloid, Acute Hematologic Neoplasms Pancreatic Adenocarcinoma Breast Cancer Colorectal Cancer Cartilage Injury of Knee Metastatic Colorectal Cancer Lupus Nephritis Optic Neuritis Prostate Cancer Metastatic Growth Hormone Deficiency Relapsing-Remitting ONO-4641 Sarizotan Tecemotide (L-BLP25) Rebif®

79Open jobs91Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Scientist, LNP Discovery BiologyBillerica, Massachusetts, United StatesOct 22, 2026Oct 22, 2026
Vice President, New Product Planning & Launch ExcellenceBoston, Massachusetts, United StatesOct 22, 2026Oct 21, 2026
Principal Medical WriterBillerica, Massachusetts, United StatesOct 22, 2026Oct 23, 2026
Senior Manager, Medical Information - Rare Tumors and OncologyBoston, Massachusetts, United StatesOct 21, 2026Oct 22, 2026
Principal Scientist, LNP Discovery BiologyBillerica, Massachusetts, United StatesOct 21, 2026Oct 22, 2026

See all 79 jobs

Timeline

  1. Trial start Phase 2: Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) source ↗
  2. Trial start Phase 1: Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer source ↗
  3. Trial start Phase 4: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate source ↗
  4. Trial start Phase 3: Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer source ↗
  5. Trial start Phase 4: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use source ↗
  6. Trial start Phase 2: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma source ↗
  7. Trial start Phase 1: First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies source ↗
  8. Trial start Phase 2: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus source ↗
  9. Trial start Phase 1: Relative Bioavailability of Pimasertib in Cancer Patients source ↗
  10. Trial start Phase 2: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) source ↗
  11. Trial start Phase 2: Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer source ↗
  12. Trial start —: Adherence Trial With MS LifeLines ® Services source ↗
  13. Trial start Phase 2: A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee source ↗
  14. Trial start II: Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma source ↗
  15. Trial start Phase 2: Tecemotide (L-BLP25) in Prostate Cancer source ↗
  16. Trial start Phase 1: MSC2015103B in Solid Tumors source ↗
  17. Trial start Phase 1: Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus source ↗
  18. Trial start Phase 1: Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors source ↗
  19. Trial start Phase 2: EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer source ↗
  20. Trial start 2: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) source ↗
  21. Trial start —: Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) source ↗
  22. Trial start Phase 4: Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial source ↗
  23. Trial start Phase 1/Phase 2: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) source ↗
  24. Trial start Phase 2: EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck source ↗
  25. Trial start Phase 1: First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors source ↗

Showing 25 of 50 dated events.

Clinical trials (lead sponsor) Showing 50 of 91

RecordTitlePhaseStatusStartPrimary completion
NCT01014936First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsPhase 1CompletedNov 30, 2009Oct 31, 2015 (actual)
NCT01013350Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical TrialsNot listedCompletedNov 30, 2009Oct 25, 2018 (actual)
NCT00093964Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)Phase 2CompletedOct 13, 2004Oct 28, 2005 (actual)
NCT02070978Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)Phase 2TerminatedJul 29, 2014Apr 5, 2016 (actual)
NCT01936363Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerPhase 2CompletedSep 30, 2013May 31, 2015 (actual)
NCT01971515First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesPhase 1CompletedDec 13, 2013Aug 9, 2018 (actual)
NCT01378377Combination Trial of Pimasertib (MSC1936369B) With TemsirolimusPhase 1TerminatedMay 27, 2011Feb 23, 2012 (actual)
NCT00105508Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaPhase 3CompletedSep 30, 2004Feb 28, 2006 (actual)
NCT00082628Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) PatientsPhase 3CompletedMay 28, 2004Sep 28, 2005 (actual)
NCT00213148Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory DysfunctionPhase 2CompletedMar 10, 2005Dec 12, 2007 (actual)
NCT00078338Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisPhase 4CompletedFeb 16, 2004Nov 28, 2006 (actual)
NCT00111839Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung CancerPhase 2CompletedMay 31, 2005Jul 31, 2007 (actual)
NCT00105521Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaPhase 3CompletedSep 30, 2004Mar 31, 2006 (actual)
NCT01496131Tecemotide (L-BLP25) in Prostate CancerPhase 2CompletedOct 24, 2011Nov 25, 2016 (actual)
NCT01085318Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialPhase 4CompletedJun 30, 2010Feb 29, 2012 (actual)
NCT01693068Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaIICompletedDec 5, 2012Jul 4, 2015 (actual)
NCT01972568Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusPhase 2Completed2013-122016-04 (actual)
NCT02049151Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung CancerPhase 3Terminated2014-032015-07 (actual)
NCT00957580Trial of Pimasertib in Hematological MalignanciesPhase 2TerminatedSep 30, 2009Dec 31, 2012 (actual)
NCT00408967Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.Phase 2WithdrawnDec 31, 2006May 31, 2008 (actual)
NCT01992874Relative Bioavailability of Pimasertib in Cancer PatientsPhase 1CompletedNov 30, 2013May 31, 2014 (actual)
NCT01016483Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerPhase 1/Phase 2CompletedNov 30, 2009Dec 31, 2013 (actual)
NCT01453387MSC2015103B in Solid TumorsPhase 1Terminated2011-092013-07 (actual)
NCT00853762Atacicept in Multiple Sclerosis Extension Study, Phase IIIITerminated2009-032009-09 (actual)
NCT02019550Rebif® Rebidose® Versus Rebiject II® Ease-of-UsePhase 4Completed2014-032016-01 (actual)
NCT01390818Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 1Completed2011-052015-04 (actual)
NCT01040832EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckPhase 2Completed2009-122012-01 (actual)
NCT00813943Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter StatusPhase 2Completed2009-032013-02 (actual)
NCT02117050RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl FumaratePhase 4Terminated2014-062015-04 (actual)
NCT00314288Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaPhase 2Completed2002-07Not listed
NCT00073541A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian CancerPhase 2Completed2003-042004-03 (actual)
NCT01689337A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the KneePhase 2Terminated2013-042013-10 (actual)
NCT01973608MSB0010445 and Stereotactic Body Radiation Therapy in Advanced MelanomaPhase 2Terminated2014-012015-04 (actual)
NCT02083679Sym004 in Subjects With Stage IV Non-small Cell Lung CancerPhase 1Terminated2014-072015-08 (actual)
NCT01085331MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)Phase 1/Phase 2Terminated2010-032012-04 (actual)
NCT01226745Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)2Terminated2010-102015-01 (actual)
NCT00642902A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)2Terminated2008-042009-09 (actual)
NCT01963611Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)Phase 2Terminated2013-102015-03 (actual)
NCT00573157The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisPhase 2/Phase 3Terminated2007-122009-04 (actual)
NCT00624338Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)2Completed2008-012012-04 (actual)
NCT00430495A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)2Completed2006-122009-09 (actual)
NCT00624468Atacicept in Subjects With Optic NeuritisPhase 2Terminated2008-062009-09 (actual)
NCT00595413Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)Phase 2Completed2007-092009-10 (actual)
NCT01360840EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate CancerPhase 2Completed2011-042013-04 (actual)
NCT00409188Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)Phase 3Completed2007-012012-04 (actual)
NCT00110396Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisPhase 3Completed2005-012007-04 (actual)
NCT00689260Easypod United States User TrialPhase 4Completed2008-032009-05 (actual)
NCT01207648Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)Not listedCompleted2010-072011-07 (actual)
NCT01905527Adherence Trial With MS LifeLines ® ServicesNot listedTerminated2013-072015-01 (actual)
NCT00689221Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter StatusPhase 3Completed2008-092012-11 (actual)

Open jobs 79

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Scientist, LNP Discovery BiologyBillerica, Massachusetts, United StatesOct 22, 2026Oct 22, 2026Not stated
Vice President, New Product Planning & Launch ExcellenceBoston, Massachusetts, United StatesOct 22, 2026Oct 21, 2026Not stated
Principal Medical WriterBillerica, Massachusetts, United StatesOct 22, 2026Oct 23, 2026Not stated
Senior Manager, Medical Information - Rare Tumors and OncologyBoston, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Principal Scientist, LNP Discovery BiologyBillerica, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
Equipment Engineering ManagerBreinigsville, Pennsylvania, United StatesOct 21, 2026Oct 20, 2026Not stated
Equipment Engineering ManagerAustin, Texas, United StatesOct 21, 2026Oct 21, 2026Not stated
Equipment Engineering ManagerChandler, Arizona, United StatesOct 21, 2026Oct 21, 2026Not stated
Scientist, LNP Discovery BiologyBillerica, Massachusetts, United StatesOct 21, 2026Oct 22, 2026Not stated
BPMM-0, Head of Strategy, Quality and OperationBillerica, Massachusetts, United StatesOct 20, 2026Oct 12, 2026Not stated
Head of Corporate Affairs, USAWashington, District of Columbia, United StatesOct 20, 2026Oct 20, 2026Not stated
Associate Director, Protein Sciences (Billerica MA)Billerica, Massachusetts, United StatesOct 20, 2026Oct 21, 2026Not stated
Lab Bench Scientist - Ligand-binding assaysBillerica, Massachusetts, United StatesOct 19, 2026Oct 20, 2026Not stated
Associate Director Medical Communications Fertility/HIV (Seaport)Boston, Massachusetts, United StatesOct 19, 2026Oct 20, 2026Not stated
Material Handler 2Rockville, Maryland, United StatesOct 19, 2026Oct 20, 2026Not stated
Scientist, Preclinical Pharmacology - Neuroscience & ImmunologyBillerica, Massachusetts, United StatesOct 19, 2026Oct 20, 2026Not stated
Senior Director, Head of Study Start UpBillerica, Massachusetts, United StatesOct 19, 2026Oct 20, 2026Not stated
Scientist, Preclinical Pharmacology - Therapeutic Area ExpansionBillerica, Massachusetts, United StatesOct 16, 2026Oct 17, 2026Not stated
Global Head of Scientific CommunicationBillerica, Massachusetts, United StatesOct 15, 2026Oct 12, 2026Not stated
Global Head of Medical OperationsBillerica, Massachusetts, United StatesOct 15, 2026Oct 12, 2026Not stated
Global Head of External Medical EngagementBillerica, Massachusetts, United StatesOct 15, 2026Oct 12, 2026Not stated
Senior Analyst, Revenue & Rebate OperationsBoston, Massachusetts, United StatesOct 15, 2026Oct 15, 2026Not stated
Shipper/Receiver I- 3rd ShiftJaffrey, New Hampshire, United StatesOct 15, 2026Oct 12, 2026Not stated
Director, Field-Based Medical Effectiveness (Field)Boston, Massachusetts, United StatesOct 14, 2026Oct 12, 2026Not stated
Director, Patient Centered Outcomes ResearchBillerica, Massachusetts, United StatesOct 14, 2026Oct 12, 2026Not stated
Senior Scientist- Delivery PharmacologyBillerica, Massachusetts, United StatesOct 14, 2026Oct 12, 2026Not stated
Executive AssistantBoston, Massachusetts, United StatesOct 14, 2026Oct 15, 2026Not stated
Director, Global Regulatory and Scientific PolicyWashington, District of Columbia, United StatesOct 13, 2026Oct 12, 2026Not stated
Principal Scientist - In Vitro ImmunotherapyBillerica, Massachusetts, United StatesOct 13, 2026Oct 14, 2026Not stated
Senior Counsel -US Rare TumorsBoston, Massachusetts, United StatesOct 12, 2026Oct 12, 2026Not stated
Senior Manager, Therapeutic Area CommunicationsBoston, Massachusetts, United StatesOct 8, 2026Oct 12, 2026Not stated
Senior Data & ML Ops EngineerBoston, Massachusetts, United StatesOct 8, 2026Oct 12, 2026Not stated
Senior Principal Medical WriterBillerica, Massachusetts, United StatesOct 7, 2026Oct 12, 2026Not stated
Scientist Functional GenomicsBillerica, Massachusetts, United StatesOct 6, 2026Oct 12, 2026Not stated
Senior Scientist Functional GenomicsBillerica, Massachusetts, United StatesOct 6, 2026Oct 12, 2026Not stated
Head of Science OperationsBillerica, Massachusetts, United StatesOct 2, 2026Oct 12, 2026Not stated
Global Marketing Director - Gomekli/EzmeklyBoston, Massachusetts, United StatesOct 2, 2026Oct 12, 2026Not stated
Principal Scientist, Preclinical PharmacologyBillerica, Massachusetts, United StatesOct 1, 2026Oct 12, 2026Not stated
Oncology Territory Manager, Arizona and Las VegasPhoenix, Arizona, United StatesSep 28, 2026Oct 12, 2026Not stated
Associate Director, Search and Evaluation Cardiometabolic & Endocrinology (Seaport MA) 1Boston, Massachusetts, United StatesSep 28, 2026Oct 12, 2026Not stated
Associate Director, Clinical Trial LeadBillerica, Massachusetts, United StatesSep 25, 2026Oct 12, 2026Not stated
eCommerce Staff EngineersBurlington, Massachusetts, United StatesSep 22, 2026Oct 12, 2026Not stated
Associate Director, Preclinical Pharmacology, FertilityBillerica, Massachusetts, United StatesSep 22, 2026Oct 12, 2026Not stated
Associate Director, Start-up Lead, SiteID & ActivationBillerica, Massachusetts, United StatesSep 21, 2026Oct 12, 2026Not stated
Clinical Immunogenicity LeadBillerica, Massachusetts, United StatesSep 21, 2026Oct 12, 2026Not stated
Senior Specialist, Environmental Health & SafetyBillerica, Massachusetts, United StatesSep 18, 2026Oct 12, 2026Not stated
Head Business Planning and Operations, Strategy, Portfolio and Hubs (SPH)Billerica, Massachusetts, United StatesSep 18, 2026Oct 12, 2026Not stated
Senior Medical Director, Global Clinical Development OncologyBillerica, Massachusetts, United StatesSep 17, 2026Oct 12, 2026Not stated
Medical Director, Global Clinical Development OncologyBillerica, Massachusetts, United StatesSep 17, 2026Oct 12, 2026Not stated
Manufacturing Operator 1Jaffrey, New Hampshire, United StatesSep 16, 2026Oct 12, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 79 jobs →

Feedback